While Celebrex is in trouble, new drugs and generics will all enter the market on June

In order to take an advantage on Celebrex (celecoxib, Pfizer) worth of KRW 60 billion in the anti-inflammatory drug market, domestic pharmaceutical companies are getting ready for the ‘June Air Attack’.

Celebrex, showing an effect of the arthritis treatment selectively inhibiting the COX-2 enzyme, secured its crown in the anti-inflammatory drug market with a approximate 9% increase rate.

Howe...